Author: Benzinga Newsdesk | August 12, 2025 06:15am
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.17) by 15.61 percent. This is a 42.86 percent decrease over losses of $(0.14) per share from the same period last year.